List of Excipients in API cedazuridine and decitabine
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing cedazuridine and decitabine
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Taiho Pharmaceutical Co Ltd | INQOVI | cedazuridine and decitabine | 64842-0727 | CROSCARMELLOSE SODIUM | 2030-08-22 |
| Taiho Pharmaceutical Co Ltd | INQOVI | cedazuridine and decitabine | 64842-0727 | FERRIC OXIDE RED | 2030-08-22 |
| Taiho Pharmaceutical Co Ltd | INQOVI | cedazuridine and decitabine | 64842-0727 | HYPROMELLOSE | 2030-08-22 |
| Taiho Pharmaceutical Co Ltd | INQOVI | cedazuridine and decitabine | 64842-0727 | LACTOSE MONOHYDRATE | 2030-08-22 |
| Taiho Pharmaceutical Co Ltd | INQOVI | cedazuridine and decitabine | 64842-0727 | MAGNESIUM STEARATE | 2030-08-22 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for cedazuridine and decitabine
Excipient focus: CROSCARMELLOSE SODIUM
cedazuridine and decitabine drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Taiho Pharmaceutical Co Ltd | cedazuridine and decitabine | 64842-0727 |
| >Company | >Ingredient | >NDC |
cedazuridine and decitabine drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
cedazuridine and decitabine drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Taiho Pharmaceutical Co Ltd | cedazuridine and decitabine | 64842-0727 |
| >Company | >Ingredient | >NDC |
cedazuridine and decitabine drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
cedazuridine and decitabine drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Taiho Pharmaceutical Co Ltd | cedazuridine and decitabine | 64842-0727 |
| >Company | >Ingredient | >NDC |
cedazuridine and decitabine drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
cedazuridine and decitabine drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Taiho Pharmaceutical Co Ltd | cedazuridine and decitabine | 64842-0727 |
| >Company | >Ingredient | >NDC |
cedazuridine and decitabine drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
cedazuridine and decitabine drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Taiho Pharmaceutical Co Ltd | cedazuridine and decitabine | 64842-0727 |
| >Company | >Ingredient | >NDC |
cedazuridine and decitabine drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
cedazuridine and decitabine drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Taiho Pharmaceutical Co Ltd | cedazuridine and decitabine | 64842-0727 |
| >Company | >Ingredient | >NDC |
cedazuridine and decitabine drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
cedazuridine and decitabine drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Taiho Pharmaceutical Co Ltd | cedazuridine and decitabine | 64842-0727 |
| >Company | >Ingredient | >NDC |
cedazuridine and decitabine drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
cedazuridine and decitabine drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Taiho Pharmaceutical Co Ltd | cedazuridine and decitabine | 64842-0727 |
| >Company | >Ingredient | >NDC |
cedazuridine and decitabine drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
cedazuridine and decitabine drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Taiho Pharmaceutical Co Ltd | cedazuridine and decitabine | 64842-0727 |
| >Company | >Ingredient | >NDC |
cedazuridine and decitabine drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
cedazuridine and decitabine drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Taiho Pharmaceutical Co Ltd | cedazuridine and decitabine | 64842-0727 |
| >Company | >Ingredient | >NDC |
cedazuridine and decitabine drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
